Everpar Advisors LLC Invests $918,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Everpar Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 3,884 shares of the medical research company’s stock, valued at approximately $918,000.

Several other hedge funds also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its stake in shares of Charles River Laboratories International by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,227 shares of the medical research company’s stock valued at $121,327,000 after buying an additional 21,028 shares in the last quarter. Apollon Wealth Management LLC grew its stake in shares of Charles River Laboratories International by 24.7% in the fourth quarter. Apollon Wealth Management LLC now owns 1,287 shares of the medical research company’s stock valued at $304,000 after buying an additional 255 shares in the last quarter. Private Advisor Group LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at $398,000. Channing Capital Management LLC grew its stake in shares of Charles River Laboratories International by 2.4% in the fourth quarter. Channing Capital Management LLC now owns 50,764 shares of the medical research company’s stock valued at $12,001,000 after buying an additional 1,205 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. boosted its position in Charles River Laboratories International by 7.3% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 18,120 shares of the medical research company’s stock worth $4,284,000 after purchasing an additional 1,231 shares during the period. 98.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research report on Friday, March 1st. Citigroup boosted their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Guggenheim downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. boosted their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Finally, Argus boosted their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $253.23.

Insider Transactions at Charles River Laboratories International

In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at $3,437,635. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock valued at $3,693,663 over the last ninety days. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Trading Down 0.4 %

CRL traded down $0.97 during trading on Wednesday, hitting $235.34. The company’s stock had a trading volume of 610,304 shares, compared to its average volume of 543,878. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The stock’s fifty day moving average price is $251.61 and its 200-day moving average price is $225.17. The firm has a market capitalization of $12.12 billion, a P/E ratio of 25.66, a PEG ratio of 1.83 and a beta of 1.44.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. During the same period in the prior year, the firm earned $2.98 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 7.9% on a year-over-year basis. Analysts anticipate that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).